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Abstract
Attentional deficits are a core symptom of schizophrenia. Post-mortem analyses of the
brains of schizophrenics reveal consistent abnormalities in -aminobutyric acid (GABA)
interneurons indicative of reduced cortical GABA transmission, raising the possibility
that this pathology contributes to attentional deficits. We examined whether blockade of
prefrontal cortex (PFC) GABAA receptors with bicuculline (BMI) impairs attention in rats
using the 5-choice serial reaction time task (5CSRTT). For comparison, we also
examined whether administration of the GABAA receptor agonist muscimol (MUS) would
improve attention. In parallel we examined the effects of both manipulations on activity
in an open field and on motivation using the intracranial self-stimulation (ICSS) test.
BMI increased PFC neuronal activity, as reflected by increased Fos-immunolabeling,
and impaired attention, as reflected by decreased accuracy and increased omissions.
Although increased omissions also may reflect reductions in locomotor activity
or motivation, the overall pattern of effects does not support either of these
interpretations: BMI did not affect locomotor activity, and it enhanced motivation
in the ICSS test. MUS did not affect attention, although it increased impulsive behavior
at a dose that suppressed PFC neuronal activity, as reflected by decreased Fosimmunolabeling. These impulsivity effects are not due to altered locomotor activity
(which was decreased) or motivation (which was not affected). Our data support the
hypothesis that cortical GABA neurons play an important role in regulating attention and
may have direct implications for the treatment of schizophrenia.

Keywords: attention, impulse control, GABA, bicuculline, muscimol, schizophrenia
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Introduction
Cognitive deficits, including attentional deficits, are a core feature of
schizophrenia (http://www.nimh.nih.gov/publicat/schizoph.cfm) and are refractory to
currently available antipsychotic treatments. In schizophrenia, cognitive impairments
predate the illness onset, are stable across phases of illness, and are present in nonschizophrenic first-degree relatives of people with schizophrenia (Cornblatt et al., 2001;
Chen et al., 2000). Furthermore, cognitive deficits predict patient difficulties in
maintaining employment, living independently and having meaningful social interactions
(Green et al., 2004). Understanding the biological bases of these deficits may lead to
the development of more efficacious treatments for this devastating disorder.
Pathology in -aminobutyric acid (GABA) neurons is one of the most reliable
abnormalities found in post-mortem analyses of the schizophrenic brain (Lewis et al.,
2005; Benes, 2010). For example, reduced gene expression of the 67-kilodalton
isoform of the GABA synthesizing enzyme glutamic acid decarboxylase (GAD67) and a
corresponding reduction in gene expression of the GABA uptake transporter (GAT1) are
observed in the prefrontal cortex (PFC) (Volk et al., 2000; Volk et al., 2001; for review,
see Lewis et al., 2005). These findings suggest reductions in the synthesis, release,
and reuptake of GABA in the brains of schizophrenics.
Within the prefrontal cortex (PFC), GABA neurons regulate the activity of efferent
glutamatergic pyramidal neurons (Markram et al., 2004; White, 1989). This
microcircuitry is essential for establishing neural synchrony (i.e., gamma oscilliations)
within cortical networks, including that evoked during attentional tasks (Bartos et al.,
2007; Gruber et al., 1999; Steinmetz et al., 2000). Notably, people with schizophrenia
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exhibit reduced evoked gamma oscillations during cognitive tasks (Cho et al., 2006;
Gonzalez-Burgos and Lewis, 2008). Collectively, these findings raise the possibility that
reduced GABA-mediated inhibition leads to reductions in neural synchrony and the
cognitive deficits that are characteristic of schizophrenia.
Research in laboratory animals provides support for the putative role of GABA
neurons in the regulation of cognitive function. For example, blockade of cortical
GABAA receptors impairs working memory in monkeys (Sawaguchi et al., 1989) and
attentional set-shifting in rats (Enomoto et al., 2011). The purpose of the current
experiment was to extend this research by determining if blockade of cortical GABAA
receptors with bicuculline (BMI) impairs visuospatial attention in the 5-choice serial
reaction time task (5CSRTT) in rats. The 5CSRTT is analogous to the continuous
performance task (CPT), which is used to quantify sustained attention in humans
(Robbins, 2002). Importantly, individuals with schizophrenia exhibit attentional
deficits on the CPT (Cornblatt et al., 2001; Chen et al., 2000), providing a strong
rationale for using the 5CSRTT to study the neurobiology of this disorder. For
comparison, we investigated whether low dose administration of the GABAA receptor
agonist muscimol (MUS) could enhance attentional performance. Because high doses
of MUS can inhibit PFC cortical activity, we speculated that high doses of MUS would
impair 5CSRTT performance in a manner similar to that observed following PFC lesions
(Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009; Muir et al., 1996).
We used additional tests (open field, intracranial self-stimulation [ICSS]) to determine if
these treatments can cause changes in locomotor activity or motivation, both of which
can affect performance in the 5CSRTT.
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Materials and Methods
Rats
Twenty-nine adult male Sprague-Dawley rats (Charles River Laboratories,
Raleigh NC) were used. Procedures began on approximately post-natal day 60.
The rats used in the 5CSRTT and open field tests were housed in pairs whereas those
used in the ICSS test were housed singly. All rats were maintained on a 12-h/12-h lightdark cycle (lights on at 0700h). Rats were given 1 week to acclimate to the housing
conditions with free access to food (Purina Rat Chow) and water. Rats tested in the
5CSRTT were food restricted to 85% of their free-feeding weights starting 24-h prior to
the onset of training. All rats had free access to water while in the home cage.
Experiments were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (National Academy Press, 1996) and McLean Hospital policies.

Drugs
(-)-Bicuculline methiodide (BMI) and muscimol (MUS) were purchased from
Sigma-Aldrich (St. Louis MO). Drugs were dissolved in physiological saline (0.9%).
The dose of BMI was based upon its salt form.

Surgery
Rats were anesthetized with sodium pentobarbital (65 mg/kg, IP) and treated
with atropine sulfate (0.25 mg/kg, SC) to minimize bronchial secretions. Rats were
implanted with bilateral guide cannulae (26-gauge; Plastics One, Roanoke, VA) that
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were situated at the border of infralimbic (IL) and prelimbic cortex (PrL) cortices (relative
to bregma: AP=+3.2, ML=±0.75, DV=-1.8 mm from dura [Paxinos and Watson, 1997]).
Obturators and injector needles (33-gauge) extended 1.5 mm below the guide
cannulae, into the IL/PrL. Rats in the ICSS experiment were simultaneously implanted
with a unilateral monopolar, stainless-steel electrode (0.25-mm diameter; Plastics One,
Roanoke, VA) aimed at the right medial forebrain bundle at the level of the lateral
hypothalamus (relative to bregma: AP=-2.8, ML=1.6, DV=-7.8 from dura). The
electrodes were coated with polyamide insulation except at the flattened tip. Skull
screws (one of which served as the ground) and the electrode were secured to the skull
with dental acrylic.

The 5-choice serial reaction time task (5CSRTT)
We trained the rats as described previously (Paine et al., 2009). Sessions
started with the delivery of 1 food pellet (45-mg, Bio-Serv, Frenchtown NJ); the first trial
commenced upon retrieval. A nose poke into the magazine initiated a 5-sec inter-trial
interval (ITI) and illumination of the house light. At the end of the ITI, a 1.0-sec light
stimulus was presented at the rear of one of the five stimulus locations (apertures).
Rats had up to 5 sec (limited hold) to make a response. A response in the illuminated
aperture (correct response) triggered delivery of 1 food pellet and illumination of the
magazine light, which remained illuminated for 5 sec following pellet delivery. Nose
pokes in the remaining apertures were considered incorrect responses and triggered a
5-sec time-out (TO) during which the house light was extinguished. Similarly, failure to
respond during the limited hold (i.e., an omission) triggered a 5-sec TO. The
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subsequent trial was initiated at the end of the TO period. Responses occurring during
the ITI were considered premature responses and also triggered a 5-sec TO; the same
trial was re-started at the end of the TO period. Responses occurring during the TO
period had no programmed consequences. Sessions ended after 90 trials or 30 min.
Performance measures of interest were: % accuracy ((correct responses/ [correct +
incorrect responses])*100), % omissions ([omissions/ trials completed]*100), premature
responses, magazine entries, correct response latency (the time from the stimulus
onset to a correct response) and reward latency (the time from a correct response to the
collection of the food). Subjects were considered to have acquired the task when their
accuracy was greater than 60% (chance performance in this test is 20%) and omissions
were fewer than 20% for 5 consecutive days. Upon reaching criterion performance, the
rats underwent surgery to implant guide cannulae.
Rats (n=17) were allowed to recover for 7 days and then were re-stabilized for 5
days prior to drug testing. To habituate rats to the infusion procedure they were first
infused with vehicle (VEH, 0.9% physiological saline); data from this session was
discarded. On test days, rats were infused with either BMI (0, 6.25, 12.5 or 25.0 ng/0.5
l/side) or MUS (0, 6.25, 12.5, 25.0 or 50.0 ng/0.5 l/side) immediately prior to testing
on the 5CSRTT. Drug doses for half of the rats tested with each drug were
administered in an ascending order, while the remainder of the rats received drug doses
in a descending order. There was a minimum of two drug-free days between infusions.

Locomotor Activity in an Open Field
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Following completion of dose-response relationships in the 5CSRTT, locomotor
activity was quantified in an open field. Locomotor activity was recorded in automated
(43.2 X 43.2 cm) activity chambers (MED Associates, St. Albans, VT). Each locomotor
activity session consisted of a 30 min habituation period, after which the rat was
removed from the chamber and administered a drug infusion. Immediately following the
infusion the rat was returned to the activity chamber for a 30 min test period. Activity
was assessed twice for each rat, once when VEH was infused and once when either
BMI (25.0 ng/0.5 l/side) or MUS (50.0 ng/0.5 l/side) was infused. The rats were
tested according to their previous history (e.g., rats that had received BMI in the
5CSRTT experiment were administered BMI during locomotor activity testing). The
order of vehicle versus drug administration was counterbalanced across rats. Activity
sessions were separated by at least 3-4 drug-free days.

Intracranial Self-Stimulation
Rats (n=12) used for the ICSS studies had not been used in the other tests. The
rats were trained on a continuous reinforcement schedule (FR1) to respond for brain
stimulation (Carlezon and Chartoff, 2007; Paine et al., 2009). Lever pressing resulted in
the illumination of a 2-W house light and immediate delivery of a 0.5-s train of squarewave cathodal pulses (0.1-ms pulse duration) at a set frequency of 141 Hz. Responses
during the 0.5-s stimulation period did not earn additional stimulation. The stimulation
current (200–350 A) was adjusted gradually to the lowest value that would sustain a
reliable rate of responding (at least 40 rewards per minute).
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Once rats reliably lever pressed for stimulation, they were adapted to lever press
for a descending series of stimulation frequencies. Each series consisted of 15 1-min
trials at each frequency. Each trial consisted of a 5-s ―priming‖ phase during which noncontingent stimulation was given, followed by a 50-s test phase during which the
number of responses was counted and ended with a 5-s time-out period during which
no stimulation was available. The stimulation frequency was then lowered by ~10%
(0.05 log10 units) and another trial was started. After responding had been evaluated at
each of the 15 frequencies, the procedure was repeated such that each rat was given 4
series per day (60 min of training). To characterize the functions relating response
strength to reward magnitude, a least-squares line of best fit was plotted across the
frequencies that sustained responding at 20, 30, 40, 50 and 60% of the maximum rate
using customized analysis software. The threshold for responding was defined as the
frequency at which the line intersected the x-axis (theta-0). Drug testing started when
mean thresholds varied by less than 15% over three consecutive training sessions.
Drug effects were quantified using the ―curve-shift‖ method of analysis (Carlezon
and Chartoff, 2007; Paine et al., 2009). This method can distinguish changes in
motivation (as reflected by alterations in theta-0) from changes in response
capabilities (as reflected by alterations in maximum response rates) (see
Carlezon and Chartoff, 2007). For each rat, three rate-frequency functions (―curves‖)
were determined immediately prior to drug infusions. The second and third curves were
averaged to obtain the baseline (threshold and maximal response rate) parameters.
Each rat was then infused with either BMI (0-25.0 ng/0.5 l/side) or MUS (0-50.0 ng/0.5
l/side) and tested for an additional 15-min rate-frequency curve. Rats were tested with

ATTENTIONAL DEFICITS FOLLOWING PFC GABAA ANTAGONISM

10

both BMI and MUS; rats were given at least 7-10 drug-free days before testing on the
alternate drug. Doses of each drug were administered in either an ascending or
descending fashion (counterbalanced across rats); tests with each drug dose were
separated by at least two drug-free days.

Histology
Following the last test session rats were anesthetized with sodium pentobarbital
(130 mg/kg, IP) and transcardially perfused with 0.9% NaCl followed by 4%
paraformaldehyde. A subset of animals was perfused 90 min following infusions of BMI,
MUS, or VEH; the brains from these animals were used for Fos immunohistochemistry
(see below). Following perfusions, brains were removed, post-fixed for 24 h and then
cryoprotected in 30% sucrose prior to slicing on a microtome. Sections (40 m) were
mounted on slides, stained with cresyl violet and placements assessed.

Fos Immunohistochemistry
Free-floating sections (40 m) from animals perfused 90 min following infusions
were used to confirm changes in neuronal activity following manipulations of GABA A
receptor activation. Briefly, endogenous peroxidase activity was quenched by
incubation in 0.3% H2O2 and then non-specific binding was blocked by a 2 h incubation
in AB media (0.3% Triton X-100, 2% normal goat serum (Invitrogen, Carlsbad, CA) and
1% bovine serum albumin (Sigma) in 0.01 M Tris buffered saline). Sections were then
incubated overnight with a polyclonal rabbit anti-c-Fos antibody (PC38T, Calbiochem,
La Jolla, CA; 1:10,000 diluted in AB media). The following day sections were washed,
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incubated for 1 h at room temperature in biotinylated goat anti-rabbit immunoglobulin G
secondary antibody (Vector Laboratories, Burlingame, CA; 1:200 diluted in AB media)
and then incubated with avidin-biotin-peroxidase complex (Vectastain ABC Elite kit;
Vector Laboratories) for 30 min at room temperature. Finally, sections were visualized
using 0.05% 3,3‘-diaminobenzidine tetrahydrochloride containing 0.01% H2O2 (Vector
Laboratories) for 10 min. Rinsing in Tris buffered saline terminated the reaction.

Statistical Analyses
5CSRTT data and ICSS data were analyzed using separate one-way repeated
measures ANOVAs with Dose as the within-subjects factor. Locomotor activity data
from habituation and test periods were analyzed separately using 2-way repeated
measures ANOVAs with Condition (VEH, Drug [BMI or MUS]) and Time (10, 20, 30 min)
as within-subjects factors. Significant effects were further analyzed using
Bonferroni Multiple Comparison post-hoc tests.

Results
Histology
Of the 29 rats tested, four animals were excluded (n = 1 for the BMI
5CSRTT/locomotor activity; n = 1 for the MUS 5CSRTT/locomotor activity; and n = 2 for
the ICSS experiment) from statistical analyses because their cannulae placements were
outside the IL/PrL (Figure 1, Figure 2A-B).
Fos immunohistochemistry was used to confirm that the BMI and MUS infusions
had the expected effects on PFC neuronal activity. Microinfusion of BMI (25 ng/0.5
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l/side) increased Fos-immunolabeling (Figure 2D), whereas MUS (50 ng/0.5 l/side)
decreased Fos-immunolabeling (Figure 2F) relative to that observed when VEH was
infused (Figure 2E). These data confirm that BMI and MUS infusions altered neuronal
activity at doses that were effective in the behavioral experiments.

5-Choice Serial Reaction Time Task (5CSRTT)
Intra-PFC administration of BMI (n = 7) affected accuracy (F[3, 18] = 3.20, P <
.05, Figure 3), omissions (F[3, 18] = 30.67, P < .01), and reward retrieval latency (F[3,
18] = 4.41, P < .05). BMI (25.0 ng) decreased accuracy and increased the reward
retrieval latency compared to VEH (all Ps < .05). BMI (12.5-25.0 ng) increased
omissions compared to VEH (all Ps < .05-.01). All other measures were unaffected by
BMI administration (all Fs[3, 18] < 2.48, n.s., Figure 3, Table I).
Intra-PFC administration of MUS (n = 8) affected premature responses (F[4, 28]
= 5.89, P < .05, Figure 4); MUS (50.0 ng) increased premature responses compared to
VEH (P < .05). All other measures were unaffected by MUS administration (all Fs[4, 28]
< 1.07, n.s., Figure 4, Table I).

Locomotor Activity
Across the habituation period prior to BMI and VEH infusions, locomotor activity
significantly decreased (F[2, 12] = 67.40, P < .01, Figure 5A); activity was higher during
the first 10-min compared to the remainder of the habituation period (both Ps < .01).
However, activity did not differ between the habituation period prior to VEH infusions as
compared to that prior to BMI infusions (F[1, 6] < 1.0, n.s.), nor was there a significant
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Condition X Time interaction (F[2, 12] < 1.0, n.s.). Activity significantly decreased
across the test period (F[2, 12] = 9.67, P < .01); activity was higher during the first 10min compared to the remainder of the test period (both Ps < .01). Activity was not
different when VEH was infused as compared to when BMI was infused (F[1, 6] < 1.0,
n.s.), nor was there a significant Condition X Time interaction (F[2, 12] < 1.0, n.s.).
Across the habituation period prior to MUS and VEH infusions, locomotor activity
significantly decreased (F[2, 14] = 123.34, P < .01, Figure 5B); activity was higher
during the first 10-min compared to the remainder of the habituation period (both Ps <
.01). Activity did not differ between the habituation period prior to VEH infusions as
compared to that prior to MUS infusions (F[1, 7] < 1.0, n.s.), nor was there a Condition X
Time interaction (F[2, 14] < 1.0, n.s.). Activity decreased across the test period (F[2, 14]
= 29.87, P < .01); activity was higher during the first 10-min compared to the remainder
of the test period (both Ps < .01). During the test period activity was significantly higher
when VEH infused as compared to when MUS was infused (F[1, 7] = 14.75, P < .01,
Figure 5B Inset), but there was not a significant Condition X Time interaction (F[2, 14]
= 3.19, n.s.).

Intracranial self-stimulation
A total of 10 rats were included in this portion of the experiment. Intra-PFC
infusions of BMI affected the threshold amount of stimulation required to maintain lever
pressing (i.e., Theta 0) (F[3, 27] = 6.60, P < .01, Figure 6A-C), without affecting
maximum rates of responding (F[3, 27] = 1.58, n.s.). Intra-PFC infusions of 25 ng BMI
significantly decreased the amount of stimulation required to maintain lever pressing
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compared to VEH infusions (BMI 0 ng; P < .01). In contrast, intra-PFC infusions of MUS
did not affect either ICSS thresholds or maximum rates of responding (Fs[4, 36] < 1.3,
n.s., Figure 6D-F).

Discussion
Cortical GABAergic interneurons provide recurrent inhibition to pyramidal
neurons, an effect that is postulated to stabilize cortical networks allowing for optimal
cognitive performance (Winterer and Weinberger, 2004). It has been proposed that
disruptions in GABA transmission underlie cognitive deficits in schizophrenia (Lewis et
al., 2005). Here we show that blockade of cortical GABAA receptors with BMI caused a
non-selective increase in cortical activity (as indicated by increased Fos
immunolabeling) and impaired attention as measured by reduced accuracy of
responding and increased omissions.
Reductions in accuracy are the most reliable indicator of attentional
deficits in the 5CSRTT (Robbins, 2002). Although the accuracy impairment
observed following intra-PFC BMI infusions was relatively small (~10%), it is of a
similar magnitude as that observed in some PFC lesion experiments (Passetti et
al., 2002; Passetti et al., 2003b) and following other manipulations (Passeti et al.,
2003a; Paine et al., 2007; Paine et al., 2009; Paine and Carlezon, 2009). Moreover,
the accuracy impairment was observed in combination with increased omissions,
another potential indicator of attentional deficits. Increased omissions in the
5CSRTT can be attributed to various factors including (i) attentional deficits (rats
fail to detect the stimulus presentation), (ii) motivational deficits (rats are
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unwilling to ‘work’ for the food pellet), or (iii) motor deficits (rats are unable to
respond) (Robbins, 2002). The pattern of results in the current experiment
suggest that the increased omissions following intra-PFC BMI infusions reflect
attentional deficits. Although BMI infusions increased the latency to retrieve the
sugar pellet reward, the effect was small (~300 ms) and rats exhibited normal
food-seeking behavior (i.e., magazine entries). Moreover, BMI decreased brain
reward thresholds in the ICSS test, an effect that reflects enhanced motivation
(Carlezon and Chartoff, 2007). Thus it is unlikely that the increase in omissions
results from decreased motivation to respond for a food reward. Increased
omissions may also indicate reductions in activity or motor capabilities. IntraPFC BMI infusions did not, however, affect the latency to make a correct
response, impulsive behavior (i.e., premature responding) or food-seeking
behavior in the 5CSRTT. Moreover, rats did not exhibit reductions in locomotor
activity in the open field or in the capability to respond in the ICSS test. These
data suggest that intra-PFC BMI infusions did not cause gross motor deficits that
interfered with the ability to nose-poke in the presence of the stimulus.
Combined with the small but significant deficit in accuracy, the increase in
omissions observed following intra-PFC BMI infusions most likely reflects an
attentional deficit.
Contrary to our hypothesis, stimulation of GABAA receptors with
microinjections of MUS did not affect attention at any dose tested. At the highest dose
tested—which reduced PFC activity as indicated by decreased Fos immunolabeling—
PFC MUS infusions increased impulsive behavior as indicated by an increase in
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premature responding. Increased impulsivity-like behavior cannot be easily explained
by either increased locomotor activity (locomotor activity was decreased following MUS
infusions) or increased reward sensitivity (which was unaffected by MUS infusions).
Failure to find attentional improvements following low dose MUS infusions may not be
surprising given that MUS is a full agonist at GABAA receptors, this likely results in nonselective suppression of cortical activity, rather than the selective suppression which is
likely necessary in order to synchronize specific cortical networks. Future research
investigating the role of positive allosteric modulators at GABAA receptors, which may
be better suited to selectively potentiate GABAA receptor activation, is warranted.
Moreover, the cognitive enhancing effects of positive allosteric modulators at GABAA
receptors may be more robust in models exhibiting cognitive impairments. Indeed,
GABAA positive allosteric modulators enhance novel object recognition in rats that
exhibited performance deficits following chronic phencyclidine treatment, a rodent
model of schizophrenia (Damgaard et al., 2011).
One limitation of our within-subject design is that the rats received several
infusions of the GABA drugs. To mitigate any effects of repeated treatment on
sensitivity to these drugs, we varied the order of treatment across subjects and
ensured that there were drug-free days between tests. The locomotor activity and
ICSS experiments were intended to identify major effects on motor capabilities or
motivation that could complicate interpretation of the attention tests. It remains
possible that more subtle changes in GABA receptor sensitivity could influence
our results. Our data provide a rationale for more detailed studies that are
designed specifically to evaluate if intra-PFC treatment with BMI or MUS cause
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long-term changes in sensitivity to the behavioral effects of these drugs, and
identify dose ranges of these drugs that are relevant for local microinfusions.
Studies designed to evaluate experience-dependent alterations in drug sensitivity
often involve repeated treatment and testing with a single dose (e.g., Todtenkopf
and Carlezon, 2006) and thus are beyond the scope of the present work.

Role of the PFC in attention
The 5CSRTT quantifies sustained visuospatial attention and impulse
control in rats and is analogous to the CPT used to quantify sustained attention
in humans (Robbins, 2002). We observed that over-activation and inactivation of a
region encompassing both dorsal and ventral portions of the medial PFC resulted in
dissociable deficits in the 5CSRTT. We used alterations in the expression of Fos as
an index of changes in the activity of these regions. Although Fos is widely
accepted as an indicator of neuronal activation, there are limitations of this
approach: as one example, Fos induction can occur by activation of intracellular
signaling pathways that do not necessarily lead to neuronal activation (Hoffman
and Lyo, 2002). This concern is mitigated in the present studies because the
effects of MUS and BMI on cell activity are well characterized (Majchrzak et al.,
2000; Sawaguchi et al., 1989) and the direction of our effects corresponds with
existing literature on the effects of these drugs. Over-activation of the medial PFC
impaired accuracy and increased omissions suggesting an attentional deficit, while
inactivation of the medial PFC increased premature responding suggesting increased
impulsive behavior. This contrasts with previous observations following excitotoxic
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lesions: large lesions encompassing both dorsal and ventral subregions of the medial
PFC lead to deficits in both cognitive domains, while those restricted to dorsal
subregions (e.g., anterior cingulated cortex and/or PrL) induce attentional deficits and
those restricted to ventral subregions (IL and/or orbitofrontal cortex) induce impulsive
behavior (Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009; Muir et al.,
1996). It is not entirely clear why temporary inactivation and excitotoxic lesions would
result in disparate performance deficits in the 5CSRTT, but the discrepancy might be
explained by compensatory changes that occur in projection areas following medial
PFC lesions. The PFC has top-down control over a number of subcortical structures
with a putative role in cognitive behavior (e.g., nucleus accumbens (NAc) and
hippocampus); long-term removal of this control may alter firing patterns in these
structures. For example, Pezze et al. (2009) suggested that both the attentional and
impulse control deficits resulting from large medial PFC lesions are the result of
increased D2 receptor activation in the NAc. In contrast, temporary inactivation of the
PFC decreases DA release, and hence receptor activation, in the NAc (Musare et al.,
1993). Regardless, our Fos studies provide the basis for future studies in which
electrophysiologic techniques are used to link changes in cellular activity with behavior.
Although our data indicate that the medial PFC mediates attention, they also
suggest that it is not necessary for optimal attention in well-trained animals. When the
medial PFC was temporarily taken ―off-line‖ by high doses of MUS, attention was not
impaired. In well-trained rats, subcortical structures may be sufficient to maintain
attention via habit-like responding (Yin and Knowlton, 2006; Killcross and Coutureau,
2003). In contrast, attention was impaired when the PFC was non-specifically over
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activated by BMI infusions. Not only would this over-activation disrupt neural synchrony
within the PFC microcircuitry, but it would also disrupt synchrony within PFC target
areas such as the NAc and hippocampus. It has been proposed that optimal attentional
performance results from specific activation of ‗task-relevant‘ pyramidal neurons and
suppression of ―task-irrelevant‖ pyramidal neurons by GABA-mediated recurrentinhibition (Winterer and Weinberger, 2004); effectively this would result in activation of
specific neurons in medial PFC target areas. Thus over-activation and asynchrony in
the PFC would effectively lead to disruptions in neural synchrony within target
structures. Currently, it is unclear if one specific projection area underlies the
attentional deficits observed following PFC over-activation or whether these deficits
result from disruptions across the entire neural network.
The current experiments provide new insight on how manipulations that affect
intracellular signaling processes may cause attentional deficits. For example, disrupting
the function of cyclic-AMP dependent protein kinase (PKA) or its downstream target
CREB (cyclic AMP response element binding protein) within the PFC decreases
accuracy and increases omissions in the 5CSRTT (Paine et al., 2009). Decreasing
either PKA or CREB function decreases neuronal excitability (Dong et al., 2006; Lopez
et al., 2007; Trantham-Davidson et al., 2007), but the manipulations used are not celltype specific and may therefore decrease firing of either pyramidal neurons or GABA
interneurons. Given the similarity between the attentional deficits observed following
disruption of the PKA signaling pathway and those following GABAA receptor
antagonism, we speculate that disruption of either PKA or CREB function cause
attentional deficits as a result of reduced GABA-mediated inhibition.
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Although the goal of the current experiment was to investigate the putative
role in GABAA receptors in the attentional deficits observed in schizophrenia,
attentional deficits are also involved in other psychiatric disorders (e.g., bipolar
disorder, ADHD). Dysregulation of neuronal firing could result from dysfunction
in a variety of neurotransmitter systems (e.g., dopamine, acetylcholine). Thus
although other psychiatric disorders may have different pathologies, the net
effect of these pathologies may result in cortical asynchrony and hence
attentional deficits.

Role of the PFC in Impulsive Behavior and Reward
The medial PFC, through its interactions with the NAc and ventral tegmental
area, is postulated to regulate both impulsive behavior (Pattij et al., 2007; Pezze et al.,
2009; Pezze et al., 2007) and sensitivity to reward (Tzsckentke, 2000). Moreover,
impulsive action is hypothesized to be regulated, at least in part, by an increased
motivation to obtain rewards (Fineberg et al., 2010). In the current experiment we
observed a dissociation between cortical manipulations that affected impulsive behavior
and those that affected reward sensitivity. Temporary inactivation of the medial PFC
increased impulsive behavior without affecting sensitivity to reward, while over-action of
the medial PFC increased sensitivity to reward without affecting impulsive behavior.
Thus at least in the context of the 5CSRTT and ICSS, it appears that impulsivity and
reward sensitivity can vary independently of one another.
Increased premature responding following temporary inactivation of the medial
PFC is consistent with the hypothesized role of this brain area in the regulation of

ATTENTIONAL DEFICITS FOLLOWING PFC GABAA ANTAGONISM

21

impulsive behavior or the tendency toward rapid, unplanned actions (for review see
Fineberg et al., 2010). Moreover, our findings are consistent with the observed increase
in premature responding in the 5CSRTT following excitotoxic lesions of ventral portions
of the medial PFC (Chudasama et al., 2003; Passetti et al., 2002; Pezze et al., 2009)
and with the observed increase in premature responding during a ―waiting task‖
following temporary inactivation of the PFC (Narayanan et al., 2006). The effects of
excitotoxic lesions on premature responding have been attributed to increased
activation of D2 receptors in the NAc. Indeed, D2 receptor antagonist infusions into the
NAc normalize impulsive behavior (Pezze et al., 2009). Temporary inactivation of the
PFC however, would be expected to decrease, rather than increase, NAc DA (Musare
et al., 1993, see below). Thus the same mechanism cannot account for increased
premature responding following temporary inactivation of the medial PFC. Nonetheless,
temporary inactivation and increased NAc DA following cortical excitotoxic lesions may
ultimately have the same effect on NAc medium spiny neurons (MSNs)—namely a
reduction in firing rate. A reduction in excitatory drive to the NAc reduces MSN firing
rate, as does increased D2 receptor activation (Carlezon and Thomas, 2009; Surmeier
et al., 2007). Thus reductions in MSN firing rate may underlie impulsive behavior that is
observed following removal of the medial PFC.
Over-activation of the medial PFC increased sensitivity to reward. The regulation
of reward by the medial PFC is thought to occur through a multisynaptic pathway
involving the ventral tegmental area (VTA). Indeed, intra-PFC BMI infusions enhance
burst firing of putative VTA DA neurons (Enomoto et al., 2011). Furthermore, electrical
stimulation of the PFC increases DA release in the NAc, an effect that can be
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attenuated via blockade of glutamate receptors in the VTA (Taber et al., 1995).
Similarly, application of glutamate to the PFC increases burst firing of VTA neurons and
increases DA release in the NAc, while application of a local anesthetic to the PFC
inhibits VTA neuron firing and reduces DA release in the NAc (Murase et al., 1993).

Conclusions
Acute blockade of cortical GABAA receptors increased PFC activity and caused
attentional deficits in the 5CSRTT. These findings add to a growing body of evidence
supporting a role for GABA neuron dysfunction in the cognitive deficits observed in
schizophrenia (see Lewis et al., 2005). Attentional deficits are often observed in
adolescents that are at-risk for developing schizophrenia before the onset of
other signs of the disorder; following their onset, these deficits are stable across
the course of illness (Cornblatt et al., 2001; Chen et al., 2000). Our studies in
adult rats provide the basis for future research that examines the
neurodevelopmental role of GABA dysfunction in the etiology of attentional
deficits observed in schizophrenia. In addition, we show that the utility of full GABAA
receptor agonists to treat such deficits is hampered the emergence unique cognitive
deficits, raising the possibility that positive allosteric modulators at GABAA receptors
might represent an alternative method by which alterations in GABA receptor function
could be utilized to reverse cognitive deficits in this schizophrenia.
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Table I. Effects of BMI and MUS on 5CSRTT Performance
Magazine Entries
Correct Latency (sec)
BMI
0.0
103.7 9.3
0.81  0.6
6.25
129.9  22.7
0.75  0.06
12.5
163.9  28.2
0.97  0.04
25.0
116.4  19.9
0.94  0.15
MUS
0.0
107.9  15.8
0.84  0.04
6.25
107.3  17.0
0.77  0.04
12.5
95.0  13.3
0.80  0.04
25.0
96.1  12.3
0.80  0.07
50.0
100.4  16.4
0.80  0.06
Note: Neither magazine entries or the correct response latency were affected by intraPFC infusions of bicuculline (BMI) or muscimol (MUS).
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Figure Captions
Fig 1. Schematic drawing showing the location of injector tips in the medial PFC of rats
infused with bicuculline (left, n=7) or muscimol (right, n=8) and tested in the 5choice serial reaction time task. Rats were excluded (not shown) if their tips
were not within the boundary of either the prelimbic (PrL) or infralimbic (IL)
cortex. Numbers on the left indicate location forward from bregma. Adapted
from Paxinos and Watson (1997).

Fig 2. Effects of manipulating cortical GABAA receptor activation on c-Fos expression.
A) Schematic of the PFC approximating location of cannulae placements
(Paxinos and Watson, 1997). Box indicates field of view in Panel B. B)
Representative cannula placements indicating guide cannulae and obturator;
injectors were the same length as the obturator. C) Schematic of the PFC
approximating the field of view in Panels D-F (Paxinos and Watson, 1997). IntraPFC infusions of the GABAA receptor antagonist bicuculline (BMI; 25.0 ng/0.5
l/side) increased c-Fos expression (D), while intra-PFC infusions of the GABAA
receptor agonist muscimol (MUS; 50.0 ng/0.5 l/side) decreased c-Fos
expression (F) relative to vehicle (VEH) infusions (E). All infusions were
administered 90 min before the rats were killed. PrL, Prelimbic cortex; IL,
infralimbic cortex.

Fig 3. Effects of intra-PFC infusions of the GABAA receptor antagonist bicuculline on
performance in the 5-choice serial reaction time task. Intra-PFC infusions of
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bicuculline (n=7) decreased accuracy (P < .05) (A) and increased both omissions
(P < .01) (B) and the reward retrieval latency (P < .05) (D). Bicuculline infusions
did not affect premature responses (C). **P < .01, *P < .05 from 0.0 (Bonferroni
Multiple Comparison test).

Fig 4. Effects of intra-PFC infusions of the GABAA receptor agonist muscimol on
performance in the 5-choice serial reaction time task. Intra-PFC infusions of
muscimol (n=8) increased premature responses (P < .05) (C), but did not affect
accuracy (A), omissions (B) or the reward retrieval latency (D). *P < .05 from 0.0
(Bonferroni Multiple Comparison test).

Fig 5. Effects of modulating cortical GABAA receptor activation on locomotor activity.
Rats were habituated to the chambers for 30 min, infused with bicuculline (BMI;
25.0 ng/0.5l/side; n=7), muscimol (MUS; 50.0 ng/0.5l/side; n=8) or their
respective vehicles (VEH) and tested for an additional 30 min. Inset shows total
activity during the habituation and test sessions. BMI did not affect locomotor
activity (A). During the test, MUS decreased the total locomotor activity (P < .01)
(B), but there was not a significant time X condition interaction. **P < .01 from
VEH (main effect of Condition).

Fig 6. Effects of modulating cortical GABAA receptor activation on intra-cranial selfstimulation thresholds. Representative rate-frequency curves from rats (n=10)
that received intra-PFC infusions of either A) bicuculline (BMI; 25.0 ng/0.5l/side)
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or D) muscimol (MUS; 50.0 ng/0.5l/side) in comparison to when they were
treated with vehicle (VEH). BMI (25.0 ng/0.5l/side) decreased the threshold for
responding (P < .01) (B) without affecting maximum rates of responding (C).
MUS did not affect either the threshold of responding (E) or the maximum rate of
responding (F). **P < .01 from 0.0 (Bonferroni Multiple Comparison test).

